Oramed Pharmaceuticals In... (ORMP)
NASDAQ: ORMP
· Real-Time Price · USD
2.31
-0.01 (-0.43%)
At close: May 01, 2025, 3:45 PM
-0.43% (1D)
| Bid | 2.24 |
| Market Cap | 94.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 4.46M |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -4.81 |
| Forward PE | -1.82 |
| Analyst | n/a |
| Ask | 2.45 |
| Volume | 17,490 |
| Avg. Volume (20D) | 238,563 |
| Open | 2.33 |
| Previous Close | 2.32 |
| Day's Range | 2.27 - 2.34 |
| 52-Week Range | 1.82 - 3.09 |
| Beta | 1.49 |
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptid...
Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2007
Employees 13
Stock Exchange NASDAQ
Ticker Symbol ORMP
Website https://www.oramed.com
Next Earnings Release
Oramed Pharmaceuticals Inc. is scheduled to release its earnings on May 16, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+19.82%
Oramed Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
10 months ago
+14.73%
Oramed Pharmaceuticals shares are trading higher after the company announced a $20 million buyback program and finalized its joint venture with Hefei Tianhui Biotech.
